β-Elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3103-3113

  Lee, Rebecca X ^a   Li, Qingdi Quentin ^a,b   Reed, Eddie ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Elemene; A2780; A2780 CP cells; Apoptosis; Cell cycle arrest; Chinese medicine; Cisplatin resistance; Ovarian cancer; P21 WAF CIP1; P53

Indexed keywords

BETA ELEMENE; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; THREONINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; DNA DEGRADATION; DOWN REGULATION; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; OVARIAN NEOPLASMS; SESQUITERPENES;

EID: 84865681019     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sfakianos GP and Havrilesky LJ: A review of cost-effectiveness studies in ovarian cancer. Cancer Control 18: 59-64, 2010.
2. Ozols RF and Young RC: Chemotherapy of ovarian cancer. Semin Oncol 11: 251-263, 1984.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage iii and iv ovarian cancer. N Engl J Med 334: 1-6, 1997.
4. Sood A and Buller R: Drug resistance in ovarian cancer: From the laboratory to the clinic. Obstet Gynecol 92: 312-319, 1998.
5. ReConte P, Bruzzone M, Chiara S, Sertoli M, Daga M, Rubagotti A, Conio A, Ruvolo M, Rosso R and Santi L: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4: 965-971,1986.
6. Kita T, Kikuchi Y, Hirata J and Nagata I: Prognosis of ovarian cancer today. Cancer J 11: 201-207, 1998.
7. Glaysher S, Yiannakis D, Gabriel FG, Johnson P, Polak ME, Knight LA, Goldthorpe Z, Peregrin K, Gyi M, Modi P, Rahamim J, Smith ME, Amer K, Addis B, Poole M, Narayanan A, Gulliford TJ, Andreotti PE and Cree IA: Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (nsclc). BMC Cancer 9: 300, 2009.
8. Kudoh K RM, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS and Chin KV: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cdna microarray. Cancer Res 60: 4161-4166, 2000.
9. Ozols R: Future directions in the treatment of ovarian cancer. Semin Oncol 29: 32-42, 2002.
10. Wang J, Zhang H and Sun Y: Phase iii clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi 18: 464-467, 1996.
11. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E and Li QQ: Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 62: 881-893, 2005.
12. Zhao J, Li QQ, Zou B, Wang G, Li X, Kim JE, Cuff CF, Huang L, Reed E and Gardner K: In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int J Oncol 31: 241-252, 2007.
13. Li QQ, Wang G, Zhang M, Cuff CF, Huang L and Reed E: Beta-elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 22: 161-170, 2009.
14. Li QQ, Wang G, Huang F, Banda M and Reed E: Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol 62: 1018-1027, 2010.
15. Li QQ, Wang G, Reed E, Huang L and Cuff CF: Evaluation of cisplatin in combination with beta-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol 107: 868-876, 2010.
16. Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J and Li J: Initial study on naturally occurring products from traditional chinese herbs and vegetables for chemoprevention. J Cell Biochem Suppl 27: 106-112,1997.
17. Zhou H, Shen J, Hou J, Qiu Y and Luo Q: Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng 22: 959-963, 2003.
18. Zou L, Liu W and Yu L: Beta-elemene induces apoptosis of k562 leukemia cells. Zhonghua Zhong Liu Za Zhi 23: 196-198, 2001.
19. Hartwell L and Weinert T: Checkpoints: Controls that ensure the order of cell cycle events. Science 246: 629-634, 1989.
20. Eastman A: Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91: 223-231, 2004.
21. Carr AM: Cell cycle. Piecing together the p53 puzzle. Science 287: 1765-1766, 2000.
22. Ree A: Cell cycle-targeted therapy. Tidsskr Nor Laegeforen 124: 2479-2482, 2004.
23. Sherr C: Cancer cell cycles. Science 274: 1672-1677, 1996.
24. Sherr C: The pezcoller lecture: Cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
25. Sen S and D'Incalci M: Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307: 122-127, 1992.
26. Kerr J, Winterford C and Harmon B: Apoptosis: Its clinical significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
27. Makin G and Hickman J: Apoptosis and cancer chemotherapy. Cell Tissue Res 301: 143-152, 2000.
28. Segal-Bendirdjian E, Dudognon C, Mathieu J, Hillion J and Besancon F: Cell death signalling: Recent advances and therapeutic application. Bull Cancer 92: 23-35, 2005.
29. Parker RJ, Eastman A, Bostick-Bruton F and Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 773-777, 1991.
30. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF: Characterization of a cis-diamminedichloroplatinum (ii)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987.
31. Maines-Bandiera S, Kruk P and Auersperg N: Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 167: 729-735, 1992.
32. Porter L and Donoghue D: Cyclin b1 and cdk1: Nuclear localization and upstream regulators. Prog Cell Cycle Res 5: 335-347, 2003.
33. Wesierska-Gadek J, Gueorguieva M and Horky M: Dual action of cyclin-dependent kinase inhibitors: Induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 55: 895-902, 2003.
34. Danial NN, Korsmeyer SJ: Cell death: Critical control points. Cell 116: 205-219, 2004.
35. Orrenius S, Zhivotovsky B and Nicotera P: Regulation of cell death: The calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552-565, 2003.
36. Jourdain A and Martinou JC: Mitochondrial outer-membrane permeabilization and remodelling in apoptosis. Int J Biochem Cell Biol 41: 1884-1889, 2009.
37. Kagan VE, Bayir A, Bayir H, Stoyanovsky D, Borisenko GG, Tyurina YY, Wipf P, Atkinson J, Greenberger JS, Chapkin RS and Belikova NA: Mitochondria- targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: A new strategy in anti-apoptotic drug discovery. Mol Nutr Food Res 53: 104-114, 2009.
38. Suen DF, Norris KL and Youle RJ: Mitochondrial dynamics and apoptosis. Genes Dev 22: 1577-1590, 2008.
39. Danial NN, Gimenez-Cassina A and Tondera D: Homeostatic functions of bcl-2 proteins beyond apoptosis. Adv Exp Med Biol 687: 1-32, 2010.
40. Danial NN: Bcl-2 family proteins: Critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263, 2007.
41. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ and Los M: Apoptosis and cancer: Mutations within caspase genes. J Med Genet 46: 497-510, 2009.
42. Hajnoczky G, Csordas G, Das S, Garcia-Perez C, Saotome M, Sinha Roy S and Yi M: Mitochondrial calcium signalling and cell death: Approaches for assessing the role of mitochondrial ca2+ uptake in apoptosis. Cell Calcium 40: 553-560, 2006.
43. Gupta S, Kass GE, Szegezdi E and Joseph B: The mitochondrial death pathway: A promising therapeutic target in diseases. J Cell Mol Med 13: 1004-1033, 2009.
44. Gross A MJaKS: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
45. Andrabi SA, Dawson TM and Dawson VL: Mitochondrial and nuclear cross talk in cell death: Parthanatos. Ann NY Acad Sci 1147: 233-241, 2008.